Wednesday, 22 May 2019

You are here

Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA

Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides. A single center cross -sectional observational study was designed to conduct deeper analysis of Cardiovascular Risk Factors (CVRF) in patients with PsA, PSO without arthritis and SpA without PSO (THU 0297). Authors aimed at identifying association between CVRF and presence of either arthritis or skin disease. 

In this study of 300 patients with PSA, PSO and SpA, 29.7% reported Hypertension (HTN), 11.7% Type 2 Diabetes Melitus(T2DM) and 29% Dyslipidemia (DL). In comparison with general population entire study group comprised 100 patients with SpA without PSO (33.3%), 100 patients with PsA (33.3%) and PSO without articular disease (13%) exhibited higher prevalence of HTN and DL (p <0.005). Inside the study group though, where was no significant difference in prevalence of CVEF between all three studied diagnoses ( Fig below).

HTN was significantly associated with AINEs intake (OR 1.79; p<0.005) and disease duration (OR 1.02). No association with gender or age was found in this study.  neither PSA/SpA nor PSO were associated with development of T2DM or dyslipidemia. 

Study concluded that although prevalence of CVRF was higher in the study group comparing to general population, no significant difference was found in regards to skin vs articular disease. authors hint at association between NSAIDs use and HTN which would require further studies to specify.

image2.jpeg

 

image3.jpeg

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.

Skyrizi (risankizumab) FDA Approved for Psoriasis

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Skyrizi is an interleukin-23 (IL-23) inhibitor that was also recently approved in Canada and Japan. Skyrizi is the third IL-23 inhibitor (behind guselkumab [Tremfya] and tildrakizumab [Ilumya]) to be approved in the last year.

Higher Comorbidities in Hidradenitis Suppurativa

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

Dual IL-17 Inhibitor in Psoriasis Succeeds

Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed.